Gazyva
Gazyva ingredients
| Active ingredient | Strength |
|---|---|
| Obinutuzumab | 1000 mg/40mL |
What Gazyva is used for
The FDA lists the approved uses on the official label (below). In the EU, obinutuzumab is approved as Gazyvaro for:
Chronic lymphocytic leukaemia (CLL) Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy. Follicular Lymphoma (FL) Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma. Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen. Lupus nephritis (LN) Gazyvaro in combination with mycophenolate mofetil (MMF) is indicated for the treatm…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Gazyva
- Generic name
- Obinutuzumab
- Made by
- Genentech, Inc.
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- CD20-directed Cytolytic Antibody
- FDA approval
- Biologic licence (BLA) BLA125486
- On the US market since
- 2013
Official information
- MedlinePlus drug information (search for Obinutuzumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Gazyva?
Gazyva (Obinutuzumab) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Gazyva?
Gazyva contains Obinutuzumab (1000 mg/40mL).
Is Gazyva approved in Europe?
The same active substance is approved in the EU as Gazyvaro.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA